Market Research Blog

Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors used to treat subset of ovarian cancer. Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP inhibitors mainly indicated in few set of patients based molecular diagnostics. Several positive end points for these drugs are prolonged Progression Free Survival (PFS) and over survival rates.

Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3197 

PARP inhibitors Market: Key Players

Some of the players in the global PARP inhibitors market are AstraZeneca, AbbVie, Clovis Oncology, Medivation and Tesaro to name a few.

PARP inhibitors Market: Drivers and Restraints

PARP inhibitors market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients. Apart from aforementioned drivers, PARP inhibitors market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period.

PARP inhibitors market hindered by the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and stringent regulatory requirement for the approvals of the PARP inhibitors over the forecast period. In addition, development of PARP inhibitors have been full of up and down and late stage recall of few developmental drugs expected to hinder the market revenue growth of PARP inhibitors over the forecast period.

PARP inhibitors Market: Segmentation

PARP inhibitors market has been segmented on the basis of drug type, indication, distribution channel and Region.

Based on the drug type, the PARP inhibitors market is segmented into the following:

• Lynparza
• Niraparib
• Rucaparib
• Talazoparib
• Veliparib

Request to View TOC @ https://www.futuremarketinsights.com/ask-question/rep-gb-3197

Based on the indication, the PARP inhibitors market is segmented into the following:

• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer

Based on the distribution channel, the PARP inhibitors market is segmented into the following:

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

Buy Report Now @ https://www.futuremarketinsights.com/checkout/3197

PARP inhibitors Market: Overview

PARP inhibitors market is witnessing significant changes due to increasing opportunity owing to  rush of big Pharma companies to buy the drug discovery companies like Tesaro and Clovis who’s pipeline PARP inhibitors shown positive results. Companies like Pfizer continuously looking for investing in the companies having product pipeline of PARP inhibitors. PARP inhibitors market is highly competitive as several small and large Pharma companies are having presence in the segment with promising pipeline products or marketed products.

PARP inhibitors Market: Region-wise Outlook

Geographically, PARP inhibitors market  is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key market for PARP inhibitors market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalPARP inhibitors market by the regions over the forecast period. Asia Pacific PARP inhibitors market is anticipated to present lower growth opportunity owing to lack of regulatory protection for innovative drugs and reimbursement policies in the region.

Table Of Content

1. Executive Summary

2. Market Overview

3. Key Market Trends

4. Key Inclusions

5. Global PARP Inhibitors Market Demand (in Value or Size in US$ Mn) Analysis 2015-2018 and Forecast, 2019-2026

6. Market Background

7. Global PARP Inhibitors Market Analysis 2015-2018 and Forecast 2019-2026, by Drug Type

And So On…

Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape

Ultrasonic Diathermy Market FMI’s analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region.

Real-Time Bioprocess Raman Analyzer Market Find insights into global market scenario and segmentation on the basis of ingredients, application, source and region.

Cortisone Market FMI’s report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period.

A recent market study published by Future Market Insights (FMI) on the GLP-1 Receptor Agonist Market offers global industry analysis for 2015-2019 & opportunity assessment for 2020-2030. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the market, growth prospects of the market are obtained with utmost precision.

The report features unique and salient factors that may make a huge impact on the development of the GLP-1 Receptor Agonist Market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the market in the years to come. The report provides detailed information about the current and future growth prospects of the market in the most comprehensive way for better understanding of readers.

GLP-1 receptor agonist, also known as incretin mimetics, represents a class of medications used in the treatment of type 2 diabetes mellitus and obesity in adults. Drugs in the GLP-1 Receptor agonist include exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide. Extensive R&D is a key driver of the GLP-1 receptor agonist market. Several pharmaceutical and biotecnology development companies are engaged in R&D for the development of new formulations and molecules.

To know more about this market, request a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12346

Key Takeaways from the GLP-1 Receptor Agonist Market

• Trulicity held the largest share in terms of revenue generation in 2019
• Ozempic is expected to witness the highest growth rate between 2020 and 2030 owing to advantages like weight loss, reduction of cardiovascular risk, and controlled levels of haemoglobin
• Asia Pacific is expected to be growing at the fastest pace due to onslaught of diabetes supporting intake of GLP-1 receptor agonists

Key Segment

Drug Class

• Exenatide
• Liraglutide
• Dulaglutide
• Lixisenatide
• Others

Route of Administration

• Parenteral
• Oral

Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centres

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Key Players Operating in Global GLP-1 Receptor Agonist Market

However, some time back, Teva did confirm generic Victoza. It also stated that it had filed ANDA (abbreviated new drug application) with the US FDA, thereby asking for approval for marketing Novo Nordisk’s Victoza (Iiraglutide) injection in the US.

The global GLP-1 receptor agonist market is fragmented, with presence of a large number of small-scale and large-scale companies. Leading companies operating in the global GLP-1 receptor agonist market are: Eli Lilly and Company, Novo Nordisk, AstraZeneca, Intarcia Therapeutics, Sanofi, Jiangsu Hengrui Medicine Co., Hanmi Pharmaceutical, PegBio, Pfizer, Amgen, Innovent Biologics

Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-12346

Want more insights?

GLP-1 Receptor Agonist market, a new study from Future Market Insights, states the indications of GLP-1 Receptor Agonist market from 2015 to 2019 and presents demand projections from 2020 from 2030 on the basis of drug class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, and Others), route of administration (parenteral, oral), distribution channel (Hospitals, Clinics, Ambulatory Surgical Centres) across seven prominent regions. In other words, a snapshot of every sub-section; that too, region-wise is presented in the report by FMI.

As per ESOMAR-certified consulting firm Future Market Insights (FMI), the global companion animal specialty drugs market registered steady year-on-year (YoY) growth at 5.42% CAGR in 2021.

Increasing pet adoption is a major factor, fuelling the demand for animal nutrition and behavioural products, thereby accelerating sales. With increasing rate of obesity among the pet, demand for anti-obesity drugs have burgeoned over the past few years.

Adoption of canine and feline pets increased during the FQ-20, due to the outbreak of COVID-19 and consequent global shutdown. Adoption of dogs is quite high, especially among the geriatric population. This is expected to drive the demand for antibiotics, skin-care, and nutritional products for pets.

As per FMI, the market is expected to reach a valuation of US$ 36,104.66 Mn in 2021 owing to the increasing demand for anti-obesity drugs across veterinary clinics. Alongside this, prevalence of canine vector-borne diseases due to bacteria and protozoa infection will fuel the demand for parasiticides in the next decade.

Key Takeaways from FMI’s Companion Animal Specialty Drugs Market Study

• By product type, parasiticides will dominate the market, accounting for over 32%of global market share.
• In terms of distribution channel, veterinary clinics are expected to lead the segment contributing over 52%of value share by 2031
• In terms of technology type, drying technology is predicted to exceed US$ 89 Bnby end 2031
• The U.S. will emerge as the leading market across North America backed by the high adoption of pet dogs
• Germany and the U.K. are anticipated to lead the Europe’s Companion animal specialty drugs market, owing to the growing obesity rate in dogs
• Increasing cases of neglect and animal cruelty in India will bolster the demand for companion animal specialty drugs through 2021

Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3984

“The demand for compounded medications and anti-obesity drugs for animals will continue increasing in the coming years. This has encouraged some of the leading companies to focus on research initiatives to launch novel drugs to facilitate improved care for companion animals. This will create impressive growth opportunities in the coming years,” says the FMI analyst.

Competitive Landscape

Zoetis Inc., Merck and Co., Inc., Bayer AG, Eli Lily and Co. and Boehringer Ingelheim GmbH are the key players operating in the companion animal specialty drugs market. among others are some prominent players operating in the Companion animal specialty drugs market.

For instance, in July 2020, Boehringer Ingelheim announced the launch of two new products, NexGard and Broadline, to provide comprehensive parasite treatment for dogs and cats, to expand their product portfolio for the India market.

As per the report, key players are focusing on product introduction and launches to expand their product portfolios. Key player are also involved extensively in strategic acquisition activities which has led to severe competition among companion animal specialty drugs market players.

For example, on August 4,2021, Zoetis, the Parsippany-based animal health company announced the acquisition of a leading Australian-based Jurox’s veterinary medicines, maker of livestock and companion animal medicines.

What else is in the report?

Future market insights offers a unique perspective and actionable insights on companion animal specialty drugs market in its latest study, presenting historical demand assessment from 2016 – 2020 and projections from 2021-2031 based on product type (antibiotics, anti-inflammatory drugs, parasiticides, heartworm, behavioral products, nutritional products, anti-obesity drugs, skin care products and vaccines), distribution channel (veterinary hospitals, veterinary clinics and pharmacies and drug stores) in seven key regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Speak to Analyst, Questions Related To Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-3984

Key Questions Answered in the Report

• What is the current companion animal specialty drugs market value?

The companion animal specialty drugs market is expected to exceed US$36,104.66 Mn in 2021

• At what rate did the companion animal specialty drugs market grow between 2016 and 2020?

The companion animal specialty drugs market projected steady growth, registering a CAGR at 5.43% between 2016 and 2020.

• What are the key trends driving companion animal specialty drugs distribution?

Growing demand for compounded medications and increasing adoption of anti-obesity drugs to reduce the growing obesity rate among pets will drive the sales.

• Who are the leading players of companion animal specialty drugs?

Zoetis Inc., Merck and Co., Inc., Bayer AG, Eli Lily and Co. (Elanco), Merial (Sanofi), Ceva Santé Animale, Virbac Animal Health, and Boehringer Ingelheim GmbH, are the top players FMI identifies as key players.

• What will be the demand outlook for North America companion animal specialty drugs market?

North America’s companion animal specialty drugs market demand is set to rise at over 3.38% CAGR during the forecast period of 2021 and 2031.

The wide scope of devices in pulmonology healthcare, increased number of surgical procedures performed, and faster regulatory approvals are key factors that are expected to generate major growth opportunities in the industry for the coming decade. The pulmonology devices market is estimated to rise at an impressive CAGR of over 10% through the end of the forecast period in 2031. Growing patient awareness about COPD and asthma, and developments in associated government healthcare initiatives will support long term growth in the industry.

“Frequent technological advances, superior portability, and ease of handling for modern pulmonology devices are boosting adoption in home and alternate care settings as well. Furthermore, non-profit and government initiatives, and awareness programs, and an influx of funding for research studies have positively influenced developments within the industry,” says the FMI study.

Request a report sample to gain comprehensive market insights at

https://www.futuremarketinsights.com/reports/sample/rep-gb-13036

Pulmonology Devices Market – Primary Takeaways

• Disposable, miniaturized bronchoscopes will witness increased uptake owing to lower health risks and ease of handling.
• Chronic obstructive pulmonary disease treatment applications hold major market share, driven by its high mortality rate.
• Awareness programs and government incentives have set up Brazil as a high potential market.
• The U.S. holds major market share on the back of easier access to new healthcare technologies and major investments into medical infrastructure.

Pulmonology Devices Market – Growth Factors

• Poor atmospheric conditions and widespread prevalence of respiratory ailments is generating demand.
• Innovations in terms of home care therapeutic devices is creating lucrative growth opportunities.
• Advances in minimally invasive surgical procedures are contributing to growth within the industry.

Pulmonology Devices Market – Major Constraints

• Unfavorable reimbursement settings in many countries is a key factor holding back adoption rates.
• Risk of side effects on neonatal patients is a key challenge restraining market growth.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/13036

Expected Impact on Market by Coronavirus Outbreak

The pulmonology devices market has been moderately affected by the ongoing covid-19 pandemic. While the market has been driven by a high volume of bronchoscopy procedures. Restrictions and postponed elective medical procedures has slowed down adoption rates. In addition, restrictions on trade have disrupted supply chains for essential raw materials and components, limiting short term growth prospects.

On the other hand, the use of specialized pulmonology devices to manage cases of respiratory failures in covid-19 patients frequent innovation in respiratory care technologies, and positive demographic trends, has helped to partially mitigate losses, and will create key lucrative opportunities for revenue generation in the near future.

Competition Landscape

Leading manufacturers operating in the pulmonology devices market include but are not limited to Merit Medical Systems, Boston Scientific Corporation, Micro-Tech (Nanjing) Co. Ltd., CONMED Corporation, Hunan Vathin, Olympus Corporation, United Medical Surgical Services Ltd., Cook Medical Incorporated, Verathon Inc., Medi-Globe GmbH, and Ambu A/S.

Major players in the pulmonology devices market are invested in strategies towards portfolio expansion. This includes efforts of product development and launch in addition to strategic mergers and acquisitions for long-term revenue generation options.

The Translational and Clinical Research Institute at Newcastle University, U.K., developed the novel Exovent negative-pressure ventilator aimed towards patients with respiratory failure, with lower levels of intrusion as compared to CPAP and positive pressure ventilation. GOQii announced approval for three wearable pulmonology devices by the Central Drugs Standard Control Organization in December 2020. Further, Olympus announced the acquisition of Veran Medical Technologies for a valuation of US$ 340 million to widen its portfolio of interventional pulmonology solutions.

Download Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-13036

More on the Report

FMI provides detailed actionable insights on the pulmonology devices market. The market is segmented in terms of product (pulmonary biopsy devices, endobronchial ultrasound needles, airway stents, airway extraction baskets, and single-use bronchoscopes), indication (lung cancer, COPD, foreign body extraction, tracheal and bronchial stenosis, and others), and end user (hospitals, pulmonology clinics, and ambulatory surgical centers), across seven regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape

Medication Management System Market: Find insights on the medication management system market with analysis of statistics, segments, players, influencers, and business strategies adopted over a 10-year forecast period.

Medical Bionic Implants and Exoskeletons Market: FMI’s report on the medical bionic implants and exoskeleton market provides insights on the market for 2017-2027. The study provides insights on restraining forces, revenue sources, market leaders, and market strategies.

Cancer Tissue Diagnostics Market: An analysis on the cancer tissue diagnostics market with information on opportunities, growth levers, regional markets, restraints, regulatory policies, and strengths of market players.

Subcutaneous drugs are injected in the layer of the skin called the cutis, which comprises the epidermis and dermis. The subcutaneous parenteral route of drug delivery is effective for administrating vaccines and for sustained release drugs and for insulin, goserelin etc. Numerous pharmaceutical products are marketed and being developed for various diseases which are administered through subcutaneous routes. Drug manufactures are also majorly focusing on packaging and effective delivery options for easy administration process so as the drug can be introduced into the patient with reliability. As many pharmaceutical company are developing self-administered drugs, several subcutaneous drug delivery devices have witnessed high adoption rate. Due to this findings major opportunities now exist for innovative approaches to subcutaneous drug delivery devices for many leading players in subcutaneous drug delivery market. Subcutaneous drug delivery market is growing as various advance drug delivery devices are introduced in market such as Jet injectors, Auto injectors, Mechanical pumps etc. The subcutaneous drug delivery systems are broadly used by the end users due to the easy and reliable operating mechanism, thus generating large revenues in the subcutaneous drug delivery market. On the other hand, subcutaneous drug delivery market is gaining profit as conventional intravenous drugs are being replaced by subcutaneous drugs. The rapid technological advancement in subcutaneous injectable devices is attributed due to wearable patch pumps and wearable smart patch as they are prefilled and have thin needles, accommodates high dose volumes and flexible to use. The global subcutaneous drug delivery market is expected to witness a significant growth over the forecast period due to rising prevalence of diabetes across the globe.

To remain ‘ahead’ of your competitors, request for a sample

Subcutaneous Drug Delivery Market: Drivers and Restraints

As per WHO 422 million of adult population have diabetes in the US which represents significant population and with increasing diagnosis rate subcutaneous drug delivery market further expected witness growth. Increasing treatment seeking rate and spreading awareness about possible treatment options for diabetes is expected to fuel the subcutaneous drug delivery market. Due to self-administered drug, administration of injectable moves increasingly from practitioner offices and healthcare facilities to patient homes. As subcutaneous route of administration is effective alternative to intravenous route of administrations it is expected to future drive the growth of subcutaneous drug delivery market. With the advent of single injector device, auto injector, mechanical pumps and progress in digital medicine, it is anticipated to growth in the subcutaneous drug delivery market. Also, technical advancement like Bluetooth connectivity of glucometer also digital display and touch screen features in devices are expected to boost the demand for subcutaneous drug delivery technology market during the forecast period. Whereas, high cost of this devices may hamper the growth Subcutaneous Drug Delivery market.

Subcutaneous Drug Delivery Market: Overview

Many biological drugs such as monoclonal antibodies, protein based therapeutics are under clinical trials and subcutaneous route of administration is being investigated for their administration this is expected to contribute significantly to Subcutaneous Drug Delivery market growth. Based on product type, fillable injectors registers the highest revenue share in the subcutaneous drug delivery market owing to their reusability coupled with its less price and growing demand from patients. As high demands for the combination of innovative drug- device product such as Insulin pumps and Omnipod from Insulet from diabetic patients have contributed majorly in the growth of the market. Owing to this players are exploring new possibilities for developments in drug formulations and delivery device technology for subcutaneous drug delivery. The growing adoption rate of this subcutaneous drug delivery systems is expected to fuel the demand for the subcutaneous drug delivery market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-7676

Subcutaneous Drug Delivery Market: Regional Outlook

On the basis of geography, global paraffin physical therapy market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest shares in the global subcutaneous drug delivery market due to presence of leading manufacturer and advanced healthcare infrastructure. North America is the most lucrative Subcutaneous Drug Delivery market. Europe is expected to be second most lucrative Subcutaneous Drug Delivery market due to higher treatment seeking rate. Asia-Pacific is regarded as emerging Subcutaneous Drug Delivery market due emerging economies such as India and China coupled with improving awareness among general population about treatment options. Latin America remains least lucrative Subcutaneous Drug Delivery market due to lowest adoption of Subcutaneous Drug Delivery as a treatment option.

Subcutaneous Drug Delivery Market: Key Players

Some of the global key participants operating in subcutaneous drug delivery market are: Insulet Corporation, Becton Dickinson Company, Consort Medical, West pharmaceuticals services Inc., Ypsomed AG, Elcam Medical, Sc Pharmaceuticals Inc., Steady Med Ltd, Amgen Inc., Sensile medical AG and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

 

The report covers exhaust analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Indication

Value Chain

 

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/7676

Regional analysis includes:

 

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain)

Eastern Europe (Poland, Russia)

Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

 

Subcutaneous Drug Delivery Market: Segmentation

 

Global Subcutaneous Drug Delivery market can be segmented on the basis of Product type, Usability, Technology and Distribution channel.

 

Based on the Product type Subcutaneous Drug Delivery market is segmented as

Fillable Injectable

Prefilled Injectable

Based on the usability type Subcutaneous Drug Delivery market is segmented as:

Disposable subcutaneous drug delivery injectable

Reusable subcutaneous drug delivery injectable

Based on the Technology type Subcutaneous Drug Delivery market is segmented as:

Jet

Spring

Gas

 

Based on the Distribution Channel Subcutaneous Drug Delivery market is segmented as:

Hospital Pharmacies

Retail Pharmacies

Drug store

Online Pharmacies

 

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current, and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint